<DOC>
	<DOCNO>NCT03079999</DOCNO>
	<brief_summary>This phase II prospective , randomize , double-blind , longitudinal study evaluate whether administration aspirin delay slow tumor growth maintain improve hearing VS patient .</brief_summary>
	<brief_title>Study Aspirin Patients With Vestibular Schwannoma</brief_title>
	<detailed_description />
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neuroma</mesh_term>
	<mesh_term>Neuroma , Acoustic</mesh_term>
	<mesh_term>Neurofibromatosis 2</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Radiographic diagnosis vestibular schwannoma ( NF2associated sporadic ) . Ageâ‰¥12 year . Ability provide inform consent.Pediatric patient must provide assent addition parents'/guardians ' consent . Adult patient consent eligible participate study . Ability swallow tablet . Inability perform volumetric measurement vestibular schwannoma ( ) . Inability tolerate MRI contrast . Daily use aspirin within last two month . Occasional use aspirin pain relief exclusionary . Known allergy aspirin . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption aspirin . Pregnant lactating woman . Patients serious medical illness ( e.g . severe asthma ) option investigator could prevent participation trial . Active bleeding diathesis . Hydrocephalus brainstem compression . Febrile illness flulike illness child adolescents less 18 year age .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>